The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...

The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. Whatever happens, though ...

What do you wonder? By The Learning Network A new collection of graphs, maps and charts organized by topic and type from our “What’s Going On in This Graph?” feature. By The Learning ...

Using Bullish Candlestick Patterns To Buy Stocks Gauging the Strength of a Market Move Stochastics: An Accurate Buy and Sell Indicator Candlestick charts are a cornerstone in technical analysis ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $95.0 for DexCom over the last 3 months.

The Nasdaq 100 fell 3.8% on Monday, its biggest decline since October 2022. The sell-off hit tech especially hard, with the Magnificent 7 cohort seeing deep losses. The Nasdaq wipeout alone ...

DexCom recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact its ability ...

The warning letter identified issues in manufacturing processes and quality management system at Dexcom’s facilities in San Diego, California and Mesa, Arizona. The company did not provide details ...

(Reuters) -Medical device maker Dexcom (NASDAQ:DXCM) said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections of the company’s facilities in San Diego ...